188 related articles for article (PubMed ID: 24373108)
1. Advice from professional societies: appropriate use of NSAIDs.
Meara AS; Simon LS
Pain Med; 2013 Dec; 14 Suppl 1():S3-10. PubMed ID: 24373108
[TBL] [Abstract][Full Text] [Related]
2. Update on guidelines for the treatment of chronic musculoskeletal pain.
Schnitzer TJ
Clin Rheumatol; 2006; 25 Suppl 1():S22-9. PubMed ID: 16741783
[TBL] [Abstract][Full Text] [Related]
3. NSAIDs in the older patient: balancing benefits and harms.
McCarberg BH
Pain Med; 2013 Dec; 14 Suppl 1():S43-4. PubMed ID: 24373111
[TBL] [Abstract][Full Text] [Related]
4. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
5. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
6. Topical therapy for osteoarthritis: clinical and pharmacologic perspectives.
Altman R; Barkin RL
Postgrad Med; 2009 Mar; 121(2):139-47. PubMed ID: 19332972
[TBL] [Abstract][Full Text] [Related]
7. The NSAID dilemma: managing osteoarthritis in high-risk patients.
Roth SH; Anderson S
Phys Sportsmed; 2011 Sep; 39(3):62-74. PubMed ID: 22030942
[TBL] [Abstract][Full Text] [Related]
8. Quantifying the impact of NSAID-associated adverse events.
Fine M
Am J Manag Care; 2013 Nov; 19(14 Suppl):s267-72. PubMed ID: 24494609
[TBL] [Abstract][Full Text] [Related]
9. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
10. Controversies and advances in non-steroidal anti-inflammatory drug (NSAID) analgesia in chronic pain management.
Shah S; Mehta V
Postgrad Med J; 2012 Feb; 88(1036):73-8. PubMed ID: 22052884
[TBL] [Abstract][Full Text] [Related]
11. NSAIDs for musculoskeletal pain management:current perspectives and novel strategies to improve safety.
Atchison JW; Herndon CM; Rusie E
J Manag Care Pharm; 2013; 19(9 Suppl A):S3-19. PubMed ID: 24261788
[TBL] [Abstract][Full Text] [Related]
12. Balancing the gastrointestinal benefits and risks of nonselective NSAIDs.
Peura DA; Goldkind L
Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S7-13. PubMed ID: 16168079
[TBL] [Abstract][Full Text] [Related]
13. Results from a patient survey to assess gastrointestinal burden of non-steroidal anti-inflammatory drug therapy contrasted with a review of data from EVA to determine satisfaction with rofecoxib.
Steinfeld S; Bjørke PA
Rheumatology (Oxford); 2002 Apr; 41 Supp 1():23-7; discussion 35-42. PubMed ID: 12173277
[TBL] [Abstract][Full Text] [Related]
14. Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal.
Davies NM; Reynolds JK; Undeberg MR; Gates BJ; Ohgami Y; Vega-Villa KR
Expert Rev Neurother; 2006 Nov; 6(11):1643-55. PubMed ID: 17144779
[TBL] [Abstract][Full Text] [Related]
15. Nonsteroidal anti-inflammatory drugs.
Knodel LC; Roush MK; Barton TL
Clin Podiatr Med Surg; 1992 Apr; 9(2):301-25. PubMed ID: 1586906
[TBL] [Abstract][Full Text] [Related]
16. Complexities in the pharmacologic management of osteoarthritis pain.
McCarberg B; Tenzer P
Curr Med Res Opin; 2013 May; 29(5):539-48. PubMed ID: 23489409
[TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
18. Current and emerging treatments for mild/moderate acute ambulatory pain.
Weaver AL
Am J Ther; 2008; 15 Suppl 10():S12-6. PubMed ID: 19127123
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ
Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785
[TBL] [Abstract][Full Text] [Related]
20. Osteoarthritis therapy--are there still unmet needs?
Laufer S
Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i9-15. PubMed ID: 14752170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
